Nearly a century ago, a monumental shift in optical microscopy forever changed how scientists examine biological samples. Developed in the…
Read More
Before its recent Phase 3 LSD win, Definium modeled up to $70,000 a year for a therapy that could fill a clinical shift
New York City–based Definium Therapeutics has reached a pivotal inflection point in the rapidly evolving landscape of psychedelic medicine. Following…
Read MoreBefore its recent Phase 3 LSD win, Definium modeled up to $70,000 a year for a therapy that could fill a clinical shift
The landscape of psychiatric medicine is undergoing a profound transformation as pharmaceutical companies transition from chronic, daily-dosing regimens to high-intensity,…
Read More
FDA Approves Eli Lilly’s Once-Weekly Basal Insulin Onswik for Type 2 Diabetes Following Robust Phase III Clinical Trials
The United States Food and Drug Administration has officially granted marketing authorization to Eli Lilly and Company for Onswik, chemically…
Read More
Novo Nordisk’s ziltivekimab misses Phase 3 primary endpoint
In a significant setback for Novo Nordisk’s ambitions to diversify its cardiovascular pipeline, the company announced that its investigational human…
Read More
Before its recent Phase 3 LSD win, Definium modeled up to $70,000 a year for a therapy that could fill a clinical shift
New York City-based biotechnology firm Definium Therapeutics has reached a pivotal juncture in the development of its flagship psychedelic candidate,…
Read More
Sling Therapeutics Secures $123M in Series C Financing to Advance Pivotal Phase III Trial of First-in-Class Oral TED Treatment
Sling Therapeutics has closed a significant $123 million Series C financing round, directing the capital toward the pivotal late-stage clinical…
Read More
Before its recent Phase 3 LSD win, Definium modeled up to $70,000 a year for a therapy that could fill a clinical shift
The pharmaceutical landscape for psychiatric care is currently witnessing a paradigm shift as New York City-based Definium Therapeutics advances its…
Read More
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s
A new paradigm in therapeutic development is emerging as Remepy, a pioneering startup, successfully completed a Phase IIa clinical trial…
Read More
Weekly Gilead and Merck oral HIV regimen maintains suppression in two phase 3 trials
Recent findings presented at the 26th International AIDS Conference have underscored a significant advancement in HIV treatment, with an investigational…
Read More
